Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma

International Journal of Cancer

Volumn 131, Issue 10, 2012, Pages 2394-2401

  Sopo, Minna ^a,b   Anttila, Maarit ^a,b   Sallinen, Hanna ^a,b   Tuppurainen, Laura ^a   Laurema, Anniina ^a   Laidinen, Svetlana ^a   Hamalainen, Kirsi ^a,b   Tuunanen, Pasi ^a   Koponen, Jonna K ^a   Kosma, Veli Matti ^a,b   Heinonen, Seppo ^a,b   Alitalo, Kari ^c   Yla Herttuala, Seppo ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

carboplatin; gene therapy; ovarian carcinoma; paclitaxel; soluble VEGF receptors

Indexed keywords

ALANINE AMINOTRANSFERASE; BEVACIZUMAB; CARBOPLATIN; CREATININE; PACLITAXEL; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ARTICLE; BLOOD VESSEL PARAMETERS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE TRANSFER; IMMUNOHISTOCHEMISTRY; KIDNEY; LIVER; LUNG; MICROVESSEL DENSITY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PRIORITY JOURNAL; SPLEEN; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; GENETIC THERAPY; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PACLITAXEL; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867085787     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27495     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R,. Phase III trial of carboplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-200.
3. Folkman J,. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
4. Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, Sakahara H, Mori T,. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation of clinicopathology et patient survival and analysis of serum VEGF levels. Br J Cancer 1997; 76: 1221-27.
5. Sowter HM, Corps AM, Evans AL, Clark DE, Charnock-Jones DS, Smith SK,. Expression and localisation of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest 1997; 77: 607-14.
6. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L,. VEGF-receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-71.
7. Shibuya M,. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006; 39: 469-78.
8. Yokohama Y, Charnock-Jones DS, Licence D, Yanaihara D, Hastings JM, Holland CM, Emoto M, Umemoto M, Sakamoto T, Sato S, Mizunuma H, Smith SK,. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian cancer. Br J Cancer 2003; 88: 237-44.
9. Nishida N, Yano H, Komai K, Nishida T, Kamura T, Kojiro M,. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of the patients with ovarian carsinoma. Cancer 2004; 101: 1364-74.
10. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA,. Salvage bevacizumab (rhu MAB VEGF) based therapy after multible prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006; 102: 140-4.
11. Raki M, Rein DT, Kanerva A, Hemminki A,. Gene transfer approaches for gynecological diseases. Mol Ther 2006; 14: 154-63.
12. Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S,. Antiangiogenic gene therapy with soluble VEGFR-1, -2 and -3 reduces the growth of solid human ovarian carsinoma in mice. Mol Ther 2009; 17: 278-84.
13. Sallinen H, Anttila M, Narvainen J, Orden MR, Ropponen K, Kosma VM, Heinonen S, Yla-Herttuala S,. A highly reproducible xenocraft model for human ovarian carsinoma and application of MRI and ultrasound in longitudinal follow-up. Gynecol Oncol 2006; 103: 315-20.
14. Lin X, Zhang Q, Rice JR, Stewart DR, Nowotnik DP, Howell SB,. Improved targeting of platinum chemotherapeutics: the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur J Cancer 2004; 40: 291-7.
15. Yamashita M, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F,. Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo. Int J Cancer 2007; 120: 2243-50.
16. Gerber HP, Ferrara N,. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65: 671-80.
17. Bhardwaj S, Roy H, Karpanen T, He Y, Jauhiainen S, Hedman M, Alitalo K, Yla-Herttuala S,. Periadventitial angiopoietin-1 gene transfer induces angiogenesis in rabbit carotid arteries. Gene Ther 2005; 12: 388-94.
18. Pajusola K, Aprelikova O, Armstrong E, Morris S, Alitalo K,. Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. Oncogene 1993; 8: 2931-7.
19. Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, Oohashi H, Hara N,. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 2000; 60: 2169-77.
20. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa S, Yla-Herttuala S, Alitalo K,. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001; 7: 199-205.
21. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG, Stacker SA, Alitalo K,. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 2001; 20: 1223-31.
22. Laitinen M, Pakkanen T, Donetti E, Baetta R, Luoma J, Lehtolainen P, Viita H, Agrawal R, Miyanohara A, Friedmann T, Risau W, Martin JF, et al. Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses. Hum Gene Ther 1997; 8: 1645-50.
23. Puumalainen AM, Vapalahti M, Agrawal RS, Kossila M, Laukkanen J, Lehtolainen P, Viita H, Paljärvi L, Vanninen R, Yla-Herttuala S,. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 1998; 9: 1769-74.
24. Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, Glass CK, Sigal E, Witztum JL, Steinberg D,. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci USA 1990; 87: 6959-63.
25. Takei Y, Mizukami H, Saga Y, Yoshimura I, Hasumi Y, Takayama T, Kohno T, Matsushita T, Okada T, Kume A, Suzuki M, Ozava K,. Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector. Int J Cancer 2007; 120: 278-84.
26. Gibb RK, Taylor DD, Wan T, O'Connor DM, Doering DL, Gercel-Taylor C,. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Gynecol Oncol 1997; 65: 13-22.
27. Ellis LM, Hicklin DJ,. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8: 579-91.
28. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N,. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-99.
29. Mesiano S, Ferrara N, Jaffe RB,. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998; 153: 1249-56.
30. Limin Hu, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB,. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002; 161: 1917-24.
31. Mabuchi S, Terai Y, Morishige K, Tanabe-Kimura A, Sasaki H, Kanemura M, Tsunetoh S, Tanaka Y, Sakata M, Burger RA, Kimura T, Ohmichi M,. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res 2008; 14: 7781-9.
32. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI,. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Study. J Clin Oncol 2007; 25: 5165-71.
33. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W,. Phase II study of bevacizumab in patients with platinum resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180-6.
34. Limin Hu, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB,. Vascular endothelial growth factor Trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005; 11: 6966-71.
35. Hasumi Y, Mizukami H, Urabe M, Kohno T, Takeuchi K, Kume A, Momoeda M, Yoshikawa H, Tsuruo T, Shibuya M, Taketani Y, Ozawa K,. Soluble Flt-1 expression suppresses carsinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 2002; 62: 2019-23.
36. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in epithelial ovarian, fallopian tube and peritoneal cancer. J Clin Oncol 2009; 27: 5601-6.
37. Parameshwar JM, Manjula K, Ming HW, Cecil RS, William EG,. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res 2003; 9: 2701-10.